Uzoma Anele

Dr. Uzoma Anele

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2011 in The American Journal of Pathology
Verified
Journal Article
Closed access
CKCheryl M. Koh
Cheryl M. Koh
BGBora Gurel
Bora Gurel
SSSiobhan Sutcliffe
Siobhan Sutcliffe
MAMartin J. Aryee
Martin J. Aryee
DSDenise Schultz
Denise Schultz
AMAngelo M. De Marzo
Angelo M. De Marzo

25 February 2010 in PLOS ONE
Verified
Journal Article
Open access
PDF file
TITsuyoshi Iwata
Tsuyoshi Iwata
DSDenise Schultz
Denise Schultz
JHJessica Hicks
Jessica Hicks
GHGretchen K. Hubbard
Gretchen K. Hubbard
LMLaura N. Mutton
Laura N. Mutton
AMAngelo M. De Marzo
Angelo M. De Marzo
Lo-MYC and Hi-MYC mice develop prostatic intraepithelial neoplasia (PIN) and prostatic adenocarcinoma as a result of MYC overexpression in the mouse prostate[1]. However, prior studies have not determined precisely when, and in which cell types, MYC is induced. Using immunohistochemistry (IHC) to localize MYC expression in Lo-MYC transgenic mice, we show that morphological and molecular alterations characteristic of high grade PIN arise in luminal epithelial cells as soon as MYC overexpression is detected. These changes include increased nuclear and nucleolar size and large scale chromatin remodeling. Mouse PIN cells retained a columnar architecture and abundant cytoplasm and appeared as either a single layer of neoplastic cells or as pseudo-stratified/multilayered structures with open glandular lumina—features highly analogous to human high grade PIN. Also using IHC, we show that the onset of MYC overexpression and PIN development coincided precisely with decreased expression of the homeodomain transcription factor and tumor suppressor, Nkx3.1. Virtually all normal appearing prostate luminal cells expressed high levels of Nkx3.1, but all cells expressing MYC in PIN lesions showed marked reductions in Nkx3.1, implicating MYC as a key factor that represses Nkx3.1 in PIN lesions. To determine the effects of less pronounced overexpression of MYC we generated a new line of mice expressing MYC in the prostate under the transcriptional control of the mouse Nkx3.1 control region. These “Super-Lo-MYC” mice also developed PIN, albeit a less aggressive form. We also identified a histologically defined intermediate step in the progression of mouse PIN into invasive adenocarcinoma. These lesions are characterized by a loss of cell polarity, multi-layering, and cribriform formation, and by a “paradoxical” increase in Nkx3.1 protein. Similar histopathological changes occurred in Hi-MYC mice, albeit with accelerated kinetics. Our results using IHC provide novel insights that support the contention that MYC overexpression is sufficient to transform prostate luminal epithelial cells into PIN cells in vivo. We also identified a novel histopathologically identifiable intermediate step prior to invasion that should facilitate studies of molecular pathway alterations occurring during early progression of prostatic adenocarcinomas.

4 June 2015 in Blood
Verified
Journal Article
Open access
PDF file
UAUzoma Anele
Uzoma Anele
BLBrian V. Le
Brian V. Le
LRLinda M. S. Resar
Linda M. S. Resar
ABArthur L. Burnett
Arthur L. Burnett
Priapism is a disorder of persistent penile erection unrelated to sexual interest or desire. This pathologic condition, specifically the ischemic variant, is often associated with devastating complications, notably erectile dysfunction. Because priapism demonstrates high prevalence in patients with hematologic disorders, most commonly sickle cell disease (SCD), there is significant concern for its sequelae in this affected population. Thus, timely diagnosis and management are critical for the prevention or at least reduction of cavernosal tissue ischemia and potential damage consequent to each episode. Current guidelines and management strategies focus primarily on reactive treatments. However, an increasing understanding of the molecular pathophysiology of SCD-associated priapism has led to the identification of new potential therapeutic targets. Future agents are being developed and explored for use in the prevention of priapism.

1 July 2014 in The American Journal of Medicine
Verified
Journal Article
Closed access
ABArthur L. Burnett
Arthur L. Burnett
UAUzoma Anele
Uzoma Anele
ITIrene N. Trueheart
Irene N. Trueheart
JSJohn J. Strouse
John J. Strouse
JCJames F. Casella
James F. Casella

1 March 2015 in The Journal of Sexual Medicine
Verified
Journal Article
Closed access
PDF file
UAUzoma Anele
Uzoma Anele
ABArthur L. Burnett
Arthur L. Burnett

4 May 2015 in Current Drug Targets
Verified
Journal Article
Closed access
PDF file
UAUzoma Anele
Uzoma Anele
BMBelinda F. Morrison
Belinda F. Morrison
ABArthur L. Burnett
Arthur L. Burnett
Priapism is an erectile disorder involving uncontrolled, prolonged penile erection without sexual purpose, which can lead to erectile dysfunction. Ischemic priapism, the most common of the variants, occurs with high prevalence in patients with sickle cell disease. Despite the potentially devastating complications of this condition, management of recurrent priapism episodes historically has commonly involved reactive treatments rather than preventative strategies. Recently, increasing elucidation of the complex molecular mechanisms underlying this disorder, principally involving dysregulation of nitric oxide signaling, has allowed for greater insights and exploration into potential therapeutic targets. In this review, we discuss the multiple molecular regulatory pathways implicated in the pathophysiology of priapism. We also identify the roles and mechanisms of molecular effectors in providing the basis for potential future therapies.